Lexeo Therapeutics (LXEO) Total Liabilities (2022 - 2026)

Lexeo Therapeutics has disclosed Total Liabilities across 5 years of filings, most recently posting $18.9 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $18.9 million, down 49.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.9 million (down 49.81% YoY), and the FY2025 annual result was $22.0 million, down 26.85% from the prior year.
• Total Liabilities came in at $18.9 million for Q1 2026 at Lexeo Therapeutics, down from $22.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $143.6 million in Q2 2023 to a low of $18.9 million in Q1 2026.
• The 5-year median for Total Liabilities is $30.3 million (2024), against an average of $47.9 million.
• Across the five-year window, Total Liabilities tumbled 81.16% in 2024 and surged 39.88% in 2025, its largest moves.
• Lexeo Therapeutics' Total Liabilities stood at $25.0 million in 2022, then advanced by 5.1% to $26.3 million in 2023, then grew by 14.57% to $30.1 million in 2024, then dropped by 26.85% to $22.0 million in 2025, then retreated by 14.35% to $18.9 million in 2026.
• The last three Total Liabilities figures came in at $18.9 million (Q1 2026), $22.0 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.